Want to join the conversation?
$ABBV's worldwide net revenues for 1Q16 grew by 22% on a constant currency basis, driven primarily by continued strength of HUMIRA, both in the U.S. and internationally, post-acquisition revenues related to IMBRUVICA, market growth and geographic expansion of VIEKIRA and revenue growth from other key products including Creon and Duodopa.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.